These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29537978)

  • 1. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.
    McDonald J; Pourcher E; Nadeau A; Corbeil P
    Clin Neuropharmacol; 2018; 41(3):87-93. PubMed ID: 29537978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
    Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
    Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
    Almaraz AC; Driver-Dunckley ED; Woodruff BK; Wellik KE; Caselli RJ; Demaerschalk BM; Adler CH; Caviness JN; Wingerchuk DM
    Neurologist; 2009 Jul; 15(4):234-7. PubMed ID: 19590387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
    Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
    PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
    Tsuno N; Mori T; Ishikawa I; Bando N; Park H; Matsumoto Y; Mori I; Tanaka M; Hirano T; Nakamura Y
    Geriatr Gerontol Int; 2019 Jul; 19(7):571-576. PubMed ID: 30864298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac and Blood Pressure Safety of Transdermal Rivastigmine in Elderly Patients With Dementia With Lewy Bodies.
    Isik AT; Ates Bulut E; Dokuzlar O; Kaya D; Erken N; Dost Gunay FS; Ontan MS
    Alzheimer Dis Assoc Disord; 2020; 34(4):339-343. PubMed ID: 32809983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
    Brawman-Mintzer O; Tang XC; Bizien M; Harvey PD; Horner MD; Arciniegas DB; Raskind M; Johnson-Greene L; Martineau RJ; Hamner M; Rodriguez-Suarez M; Jorge RE; McGarity S; Wortzel HS; Wei Y; Sindowski T; Mintzer J; Kindy AZ; Donovan K; Reda D
    J Neurotrauma; 2021 Jul; 38(14):1943-1952. PubMed ID: 33514274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postural control and freezing of gait in Parkinson's disease.
    Schlenstedt C; Muthuraman M; Witt K; Weisser B; Fasano A; Deuschl G
    Parkinsonism Relat Disord; 2016 Mar; 24():107-12. PubMed ID: 26762797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
    Muñoz-Moreno JA; Prats A; Moltó J; Garolera M; Pérez-Álvarez N; Díez-Quevedo C; Miranda C; Fumaz CR; Ferrer MJ; Clotet B;
    PLoS One; 2017; 12(8):e0182547. PubMed ID: 28854283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
    Pai MC; Aref H; Bassil N; Kandiah N; Lee JH; Srinivasan AV; diTommaso S; Yuksel O
    Clin Interv Aging; 2015; 10():1779-87. PubMed ID: 26622172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.